1. Home
  2. RZLT vs ZURA Comparison

RZLT vs ZURA Comparison

Compare RZLT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

N/A

Current Price

$4.35

Market Cap

352.1M

Sector

Health Care

ML Signal

N/A

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$0.96

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RZLT
ZURA
Founded
2010
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
352.1M
455.4M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
RZLT
ZURA
Price
$4.35
$0.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
7
Target Price
★ $10.80
$8.00
AVG Volume (30 Days)
1.7M
★ 6.7M
Earning Date
11-05-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.47
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,410.31
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.92
52 Week High
$11.17
$7.25

Technical Indicators

Market Signals
Indicator
RZLT
ZURA
Relative Strength Index (RSI) 52.90 24.55
Support Level $3.58 N/A
Resistance Level $4.22 $5.97
Average True Range (ATR) 0.39 0.24
MACD 0.04 -0.18
Stochastic Oscillator 60.24 0.02

Price Performance

Historical Comparison
RZLT
ZURA

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Share on Social Networks: